Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914628 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
A Phase 3 study, sponsored by AGC Biologics S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 92
- Enrollment target
NCT00914628 is a Phase 3 study that was terminated before completion, run by AGC Biologics S.p.A.. The registered enrollment target is 92 participants.
The verdict
NCT00914628, a Phase 3 study, was terminated before completion, sponsored by AGC Biologics S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 92 participants
- Enrollment target
Study Summary
The main objective of this randomized trial is to compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard haploidentical HCT
Interventions
- GENETIC HSV-Tk
- OTHER T-cell depleted or T-cell replete strategies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2010-04-12 |
| Est. Completion | 2019-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914628
The ClinicalTrials.gov registry entry for NCT00914628 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AGC Biologics S.p.A., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HSV-Tk is the first listed.
NCT00914628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914628 about?
NCT00914628 is a clinical study titled "Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia". The main objective of this randomized trial is to compare disease-free survival (DFS) in high risk leukemia patients who underwent haploidentical HCT followed by an add back strategy of HSV-Tk donor lymphocytes or standard haploidentical HCT
What is the current status of trial NCT00914628?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 92 participants. The study started on 2010-04-12. Estimated completion is 2019-11-30.
What interventions are being tested in trial NCT00914628?
The interventions under investigation include: HSV-Tk (GENETIC), T-cell depleted or T-cell replete strategies (OTHER).
Who is sponsoring clinical trial NCT00914628?
This trial is sponsored by AGC Biologics S.p.A., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.